STAT+: Mikael Dolsten, Pfizer CSO who could take on Covid but not Wall Street, to step down

Five years ago — before the pandemic — Pfizer’s head of research and development, Mikael Dolsten, told STAT he kept a chess set in his office that he got as a gift from a former CEO of the company. It was a memento delivered to Dolsten after he cautioned his boss that research and development was a long process, like a chess match, not something that would happen quickly.

“I told him that, look, it’s not just one investment, it is like playing chess,’’ Dolsten said. “You need to have a picture of the entire opening game, win the middle game, and be really good in the end game.”

On Tuesday, Dolsten reached the end game.

Continue to STAT+ to read the full story…

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!